Alloy Therapeutics Offers Licensing Agreement with Scripps Research
Alloy Therapeutics, a biotech company focused on accessible biologics discovery, announced a licensing agreement with Scripps Research for its ATX-Gx platform, enabling all Scripps scientists to use it for antibody and vaccine discovery. The ATX-Gx platform, an industry standard for fully human antibody discovery, utilizes engineered mice with human antibody genes, facilitating efficient discovery with minimal optimization needed for clinical studies. This partnership expands ATX-Gx’s impact on vaccine development and accelerates therapeutic research across various medical fields.
Alloy Therapeutics Offers Licensing Agreement with Scripps Research